Pharmacy evidence record · researched 2026-08-20

Olympia Pharmacy

Lowlite Investments Inc. dba Olympia Pharmacy

4 citations2 action records8 explicit unknowns

Compounded with

Semaglutide

Not verified in the sources we checked.

Tirzepatide

Not verified in the sources we checked.

Product evidence does not establish current availability.

Locations in the source record

  • 6700 Conroy Rd, Suite 140, Orlando, FL 32835-3500

Services named by sources

  • 503A prescription fulfillment
  • Patient-specific compounded medications

Regulatory compliance

503 pathway evidence

A pathway label describes which federal rules apply — it is not a quality claim.

Section 503A

Source-backed pathway evidence

The current first-party homepage explicitly calls Olympia Pharmacy the affiliated 503A pharmacy. Section 503A is a statutory pathway, not FDA registration.

Section 503B

Not conclusively established

Historical FDA records also use the Olympia Pharmacy brand for OPS International's outsourcing facility. Those records were not used to assign 503B status to Lowlite Investments or the current 503A affiliate.

What remains unverified

  • Current corporate ownership and legal-name continuity
  • Current Florida pharmacy license status
  • Full state-by-state license and shipping footprint
  • Semaglutide relevance
  • Tirzepatide relevance
  • Founded year
  • Exact legal entity responsible for the 2022 recall
  • Later action disposition and comprehensive state-board history

Telehealth providers

No telehealth-provider relationship is verified in the sources we checked.

Clinic Scout links a provider only when an explicit source names the relationship.

Browse providers

Regulatory history

Actions stay dated and bounded.

The Lowlite Investments 2013 Form 483 and 2022 Olympia Pharmacy brand-level recall were verified. The recall's exact legal entity, current license status, later disposition, and complete state-board history remain unresolved.

U.S. Food and Drug Administration · 2013-03-21

Form FDA 483

FDA listed twelve observations for Lowlite Investments Inc. dba Olympia Pharmacy after a March 2013 inspection. A Form 483 is not a final agency determination.

issued

U.S. Food and Drug Administration · 2022-03-10

Voluntary Recall

FDA published Olympia Pharmacy's voluntary nationwide recall of eleven lots of compounded injectables found out of specification. The public recall page does not identify the underlying legal entity, so it is retained as brand-level history.

company_announced_brand_level_entity_not_resolved

Patient reviews

Share your experience

No Clinic Scout patient reviews are published for this pharmacy. Submissions are checked before publication.

What this page verifies for you

4 evidence checks carry a date and a source.

Each line traces to a citation in the source list below — read the exact captured wording before relying on it.

No superiority claim is made for review volume, ratings, or patient sentiment.

Sources and exact captured wording

  1. first_party · accessed 2026-08-20
    Our affiliated 503A pharmacy, Olympia Pharmacy, extends this service by providing prescription fulfillment—bringing our 503B medications directly to patients through their healthcare providers.
  2. cms_nppes · accessed 2026-08-20
    LOWLITE INVESTMENTS INC ... Doing Business As: OLYMPIA PHARMACY ... NPI: 1629204623 ... Primary Practice Address 6700 CONROY RD STE 140 ORLANDO, FL 32835-3500
  3. fda · accessed 2026-08-20
    Lowlite Investments, Inc. D/B/A Olympia Pharmacy ... DATE OF INSPECTION 03/04/2013 - 03/21/2013 ... Producer of sterile drug products
  4. fda · accessed 2026-08-20
    Olympia Pharmacy is voluntarily recalling 11 specific lots ... compounded injectables to the consumer level. These compounded products were found to be out-of-specification.

Questions readers ask

Is Olympia Pharmacy legit?

GLP Clinic Scout does not issue a blanket legitimacy verdict. This research record preserves 4 dated first-party or regulator citation(s), 2 regulatory/action record(s), and 9 explicitly unresolved field(s). Review the cited evidence and current license status before making a decision.

Still have questions? Read the research library or email us at [email protected].